CAR T Cell Therapy: Breakthroughs, Challenges, and the Road Ahead

CAR T cell therapy has emerged as one of the most promising advances in cancer treatment, offering a 'living drug' that reprograms a patient’s immune cells to target and destroy cancer. Since its first approval in 2017, the therapy has transformed outcomes for patients with blood cancers, but significant challenges remain—particularly in expanding its use to solid tumors and improving accessibility.

How CAR T Cell Therapy Works

CAR T cell therapy is a form of immunotherapy that genetically reprograms a patient’s T cells—immune cells that play a critical role in fighting infections and diseases—to target and attack cancer cells. According to Gizmodo, the process involves extracting T cells from the patient’s body, modifying them in a lab to express receptors that recognize a specific antigen on cancer cells, and then infusing them back into the patient.

This approach effectively turns the modified T cells into a 'living drug,' capable of persisting in the patient’s body and providing long-term defense against cancer. Unlike traditional drugs, which are metabolized and eliminated, CAR T cells can perpetuate and adapt, offering sustained protection.

Successes and Approvals

CAR T cell therapy received its first U.S. approval in 2017 for several blood cancers that had not responded to earlier treatments. According to reporting by Gizmodo, the therapy has since delivered remarkable results, with a significant percentage of patients achieving sustained remission or even complete cures. This success has positioned CAR T as a transformative option for patients with few alternatives.

The therapy’s impact is underscored by recognition in the medical community. Renier Brentjens, Deputy Director and Chair of the Department of Medicine at Roswell Park Comprehensive Cancer Center, was one of four scientists awarded by the Warren Alpert Foundation in 2024 for their pivotal role in developing CAR T therapy. Brentjens and his colleagues at Memorial Sloan Kettering are credited with coining the term 'CAR T.'

Challenges and Limitations

Despite its success, CAR T cell therapy faces significant challenges. According to Gizmodo, the treatment is expensive and time-consuming, requiring weeks to extract, modify, and reinfuse a patient’s cells. This complexity limits its accessibility and scalability.

The therapy is also associated with serious side effects, including cytokine release syndrome, a potentially life-threatening immune response. Additionally, antigen escape—a phenomenon where cancer cells stop expressing the target antigen—can render the treatment ineffective over time.

Efforts to create 'off-the-shelf' CAR T cells or in vivo approaches (where reprogramming occurs inside the patient’s body) are underway. However, Gizmodo reports that these methods have not yet proven superior to the current autologous approach, which uses the patient’s own cells.

The Future of CAR T Therapy

While CAR T therapy has revolutionized the treatment of blood cancers, its application to solid tumors remains a major challenge. Solid tumors are more immunologically complex and harder to target than blood cancers, making them less responsive to current CAR T constructs.

Researchers are exploring next-generation CAR T designs that could overcome these limitations. For example, modifying T cells to express additional functions, such as cytokines, could enhance their effectiveness. Reducing costs and streamlining production are also key priorities to make the therapy more widely available.

The goal is to expand CAR T’s reach beyond blood cancers and establish it as a viable option for a broader range of patients. However, achieving this will require advances in both science and business models to address the therapy’s current constraints.

What this means

LazyFounders analysis — our interpretation, not reported fact.

CAR T cell therapy represents a paradigm shift in oncology, moving beyond traditional drug-based treatments to a more dynamic, immune-system-driven approach. For founders and operators in biotech and healthcare, this therapy exemplifies the potential of precision medicine—but also the hurdles of scalability, cost, and technical complexity.

The success of CAR T in blood cancers proves that cell-based therapies can work, but its limitations highlight the need for innovation in manufacturing, targeting, and affordability. As research expands into solid tumors, there’s an opportunity for startups to explore next-generation CAR T constructs, off-the-shelf solutions, or complementary technologies that address antigen escape or reduce side effects.

For investors and operators, the lesson is clear: breakthrough therapies don’t just require scientific advances—they demand business models that can make them accessible to patients. The high cost and time-intensive production of CAR T underscore the need for disruptive approaches to democratize cutting-edge treatments.

Key takeaways

• CAR T cell therapy reprograms a patient’s immune cells to target and attack cancer, offering a 'living drug' that persists in the body.
• Approved in 2017 for blood cancers, the therapy has led to sustained remission or cures for many patients with difficult-to-treat forms of the disease.
• Despite its success, CAR T faces challenges like high costs, lengthy production, side effects (e.g., cytokine release syndrome), and antigen escape.
• Solid tumors remain a major hurdle due to their complexity and the immune system’s difficulty in targeting them effectively.
• Future directions include next-generation CAR T constructs, cost reduction, and expanding applications to solid tumors.

FAQ

What is CAR T cell therapy?

CAR T cell therapy is a form of immunotherapy that involves genetically modifying a patient’s T cells to recognize and attack cancer cells. These modified cells act as a 'living drug,' persisting in the body to provide long-term protection.

How successful is CAR T therapy for blood cancers?

CAR T therapy has shown significant success in treating blood cancers, with many patients achieving sustained remission or even complete cures. It is particularly effective for patients who have not responded to other treatments.

What are the main challenges of CAR T therapy?

Key challenges include high costs, time-consuming production, side effects like cytokine release syndrome, and limitations such as antigen escape, where cancer cells evade the treatment by stopping expression of the target antigen.

Can CAR T therapy treat solid tumors?

Currently, CAR T therapy is less effective for solid tumors due to their complexity and the difficulty of targeting them. Research is ongoing to develop next-generation CAR T constructs that could address these challenges.

Why is CAR T therapy so expensive?

The therapy requires extracting and genetically modifying a patient’s T cells over several weeks, a complex and labor-intensive process. This drives up costs and limits accessibility.

Related on LazyFounders

• More health news